Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258854 · ClinicalTrials.gov registry record · Phase 3
An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
A Phase 3 study, sponsored by Xoma (US).
- Terminated
- Registry status
- Phase 3
- Development phase
- 69
- Enrollment target
NCT02258854 is a Phase 3 study that was terminated before completion, run by Xoma (US). The registered enrollment target is 69 participants.
The verdict
NCT02258854, a Phase 3 study, was terminated before completion, sponsored by Xoma (US).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.
Interventions
- DRUG Dose 2 gevokizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2014-03 |
| Est. Completion | 2017-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02258854
The ClinicalTrials.gov registry entry for NCT02258854 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dose 2 gevokizumab is the first listed.
NCT02258854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02258854 about?
NCT02258854 is a clinical study titled "An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data". The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.
What is the current status of trial NCT02258854?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 69 participants. The study started on 2014-03. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02258854?
The interventions under investigation include: Dose 2 gevokizumab (DRUG).
Who is sponsoring clinical trial NCT02258854?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.